Health
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achievedWegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular riskData on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analogues Ba
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular risk","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Data on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analogues","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":497,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 28 April 2026 – Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey. The full data, 52 abstracts, span Wegovy® (semaglutide 2.4 mg), higher-dose Wegovy® (semaglutide 7.2 mg), Wegovy® pill (oral semaglutide 25 mg), and CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg), an investigational first-in-class combination of a GLP-1 receptor agonist and a long-acting amylin analogue.","length":480,"tagName":"p"},{"type":"text","content":"Together, these data reinforce Novo Nordisk’s position as the scientific leader in obesity treatment, with the broadest portfolio of approved and pipeline GLP-1-based therapies.","length":177,"tagName":"p"},{"type":"text","content":"“Novo Nordisk is looking forward to presenting compelling data at ECO, which highlight benefits of our treatments for people living with obesity, including women dealing with health challenges during all phases of menopause,” said Martin Holst Lange, chief scientific officer and head of Research &...